NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPATCH is a transdermal estradiol/norethindrone acetate combination patch approved for treating moderate to severe vasomotor symptoms (hot flashes) in menopausal women with an intact uterus. It delivers estrogen and progestin through the skin as an extended-release film, providing continuous hormone replacement therapy.
$5MPart D
LOE ApproachingDeclining
Product faces near-term loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward lifecycle management and generic transition roles.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Career Relevance
Career opportunities on COMBIPATCH are heavily concentrated in Quality Assurance and Manufacturing Engineering, reflecting the product's mature lifecycle and focus on supply chain efficiency and compliance. With only 7 linked job openings and primarily manufacturing-focused roles, this product offers specialized technical career development but limited commercial growth trajectories.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.